Funding for biotech startups had its best quarter in two years — sort of
Privately held drug developers raised about $6.7 billion in the second quarter, marking the best three-month stretch since the beginning of 2022 and the tail …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
